However, although these findings and that the results from CVOTs have suggested a potential reduction in hospitalization for heart failure with GLP-1 receptor agonists—estimated at approximately 10–11% in recent meta-analyses [54,56]–the findings from dedicated trials have been less encouraging. Here, GLP1R is linked to heart failure.